Skip to content

Study · Animal study (in vivo) · mouse · 2019

2 results

Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy.

Hong Y, Lee JH, Jeong KW, Choi CS, Jun HS

Journal of cachexia, sarcopenia and muscle24 Apr 2019Cited by 156 (Europe PMC)

PMID31020810 (opens in a new tab)PMCIDPMC6711418 (opens in a new tab)DOI10.1002/jcsm.12434 (opens in a new tab)PepBankPUB-31020810
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In DBA/2J-mdx mice, dulaglutide recovered muscle mass.

    In plain wordsIn mice with muscular dystrophy, dulaglutide restored muscle mass.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseMuscle mass
    Study

    mousen: not reported in source

    DBA/2J-mdx Duchenne muscular dystrophy model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    1 mg/kg/week · subcutaneous · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In addition, treatment with a long-acting GLP-1R agonist, dulaglutide, recovered muscle mass and function in DBA/2J-mdx mice.
    1 context sentence
    Summary · context
    Furthermore, we evaluated the effect of a long-acting GLP-1R agonist by treatment of dulaglutide (1 mg/kg/week s.c.) for 3 weeks, in DBA/2J-mdx mice, a Duchenne muscular dystrophy model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In DBA/2J-mdx mice, dulaglutide recovered muscle function.

    In plain wordsIn mice with muscular dystrophy, dulaglutide restored muscle function.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseMuscle function
    Study

    mousen: not reported in source

    DBA/2J-mdx Duchenne muscular dystrophy model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    1 mg/kg/week · subcutaneous · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In addition, treatment with a long-acting GLP-1R agonist, dulaglutide, recovered muscle mass and function in DBA/2J-mdx mice.
    1 context sentence
    Summary · context
    Furthermore, we evaluated the effect of a long-acting GLP-1R agonist by treatment of dulaglutide (1 mg/kg/week s.c.) for 3 weeks, in DBA/2J-mdx mice, a Duchenne muscular dystrophy model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 2NCT07747805

GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

The Cleveland Clinicn = 30est. 28 Aug 2026 to est. 15 Aug 2029

COPD · Obesity & Overweight · Sarcopenia

Trial pageClinicalTrials.govUpdated 5 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.